

**GOCCHI**

**Country:** Chile

**Group:** Chilean Cooperative Group for Oncologic Research  
**(GOCCHI)**

---

**Chairman:** Dr J. Gutiérrez  
GOCCHI  
Chilean Cooperative Group for Oncologic Research  
Eliodoro Yáñez 2967, Depto. 41  
Providencia, SANTIAGO  
CHILE  
Tel: +56 2 233 0798  
Fax: +56 2 231 0983  
Email: jgutierrez@clinicalascondes.cl

**Vice-Chairwoman:** Dr L. Bronfman  
Email: luciabronfman@entelchile.net

**Scientific Director:** Dr R. Arriagada  
Email: arriagada@igr.fr

**Secretary:** Dr R. Schwartz  
Email: rschwartz@utr.net

**Treasurer:** Dr A. Pinto  
Email: rschwartz@utr.net

**Directors:** Dr N. Aliaga  
Email: naliagam@vtr.net

Dr R. Baeza  
Email: ramon.baeza@iram.cl

Dr A. Corvalán  
Email: corvalan@med.puc.cl

Dr C. del Castillo  
Email: darfa@vtr.net

Dr J. Madrid  
Email: madrid@iram.cl

Dr A. Majlis  
Email: amajlis@entelchile.net

Dr B. Müller  
Email: [bmuller@manquehue.net](mailto:bmuller@manquehue.net)

Dr Peralta  
Email: [octavioperalta@entelchile.net](mailto:octavioperalta@entelchile.net)

Dr C. Ramos  
Email: [christianramos@terra.cl](mailto:christianramos@terra.cl)

**Data Manager:** Ms M. Zúñiga  
Email: [maricarmen@gocchi.org](mailto:maricarmen@gocchi.org)

**Regulatory Trials  
Coordinator:** Mrs M.F. Chinchón  
Email: [datacenter@gocchi.org](mailto:datacenter@gocchi.org)

**CRA:** Mrs. C. Mariani  
Email: [cmariani@gocchi.org](mailto:cmariani@gocchi.org)

**Accountant and  
Computer  
Programmer:** Mr C. Díaz  
Email: [cdiaz@gocchi.org](mailto:cdiaz@gocchi.org)

**Website:** <http://www.gocchi.cl/>

**Title:** Molecular marker for dissemination in breast carcinoma.

---

**Coordinator(s):** Dr J. Gutiérrez  
GOCCHI  
Chilean Cooperative Group for Oncologic Research  
Eliodoro Yáñez 2967, Depto. 41  
Providencia, SANTIAGO  
CHILE  
Tel: +56 2 233 0798  
Fax: +56 2 231 0983  
Email: jgutierrez@clinicalascondes.cl

Dr A. Corvalán  
Department of Pathology  
Catholic University of Chile  
85 Lira St  
SANTIAGO  
CHILE  
Email: corvalan@med.puc.cl

**Summary:**

- To identify specific oncogenes and tumour suppressor genes in 10 retrospectively collected breast carcinomas, 5 without lymph node metastases and 5 with lymph node metastases using cDNA microarray technology. The five most relevant genes will be confirmed by RealTime PCR and tumour suppressor genes with significant down regulation will be evaluated for epigenetic inactivation. If confirmed, plasma from independent group of cases will be tested for selected genes for evaluation as clinical markers for dissemination.

**Scheme:** None available

**Update:**

- Started March 2005; proposed end date, December 2007.

**Related Publications:** Abstract presented at the Latin American Congress of Breast Cancer, November 2005, Santiago, Chile.

**Topics:**

- Breast carcinoma
- Epigenetics
- Methylation

**Keywords:** Breast carcinoma, molecular markers, RealTime PCR